RUA Life Sciences is a holding company for a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM).
Review of interims, issue, and strategic update
RUA have announced its interim results ending 30 September 2023 and together with the previous...
Read moreFundraising looks well supported
RUA have announced, subject to shareholder approval at a General Meeting, the intention to raise...
Read moreTrading Update
RUA have released a trading update ahead of its December interim results announcement. In contrast...
Read moreStrategy Update, sticking to its objectives
In place of the trading statement which is usually released at this time of year, and ahead of RUA...
Read morePositive AGM Statement & Trading Update
RUA Life Sciences’ AGM statement provided tangible progress on its heart valve and vascular graft...
Read moreFinal FY 2023 results
RUA Life Sciences final results for FY 2023 were in line with the earlier trading statement and...
Read moreFY2023 Trading Update - welcome regulatory and R&D progress
RUA Life Sciences trading update included Group revenues and year-end cash position were modestly...
Read moreCommercialisation partnership signed
RUA’s global commercialisation partner for its range of large bore vascular grafts has been...
Read more
Messages from the interim results
RUA Life Sciences’ interim results include in-depth updates on the development of its vascular...
Read morePositive trading and regulatory update
RUA Life Sciences’ trading update was accompanied by a regulatory update on its vascular graft...
Read more- Prev
- 1 of 4 pages
- Next
Register to be first
Get research on the companies that interest you straight to your inbox
